Featured Research

from universities, journals, and other organizations

Alcohol Researchers Identify New Medication That Lessens Relapse Risk

Date:
September 1, 1999
Source:
NIH-National Institute On Alcohol Abuse And Alcoholism
Summary:
A study in the current Archives of General Psychiatry (Volume 56, pages 719-724) shows that nalmefene, an opioid antagonist that is not now commercially available in the oral form studied, is effective in preventing relapse to heavy drinking in alcohol dependent individuals.

A study in the current Archives of General Psychiatry (Volume 56, pages 719-724) shows that nalmefene, an opioid antagonist that is not now commercially available in the oral form studied, is effective in preventing relapse to heavy drinking in alcohol dependent individuals. Barbara J. Mason, Ph.D., and colleagues at the University of Miami School of Medicine found from a 12-week double-blind, placebo-controlled clinical trial that patients who received nalmefene were 2.4 times less likely to relapse to heavy drinking than those who received a placebo.

"This study again demonstrates the promise of pharmacologic agents to work with standard behavioral treatments in the treatment of alcoholism. Prospects for improving treatment outcome have never been better," said Enoch Gordis, M.D., Director, National Institute on Alcohol Abuse and Alcoholism, a component of the National Institutes of Health.

Naltrexone, another opioid antagonist that is selective for the mu receptor, was approved by the U.S. Food and Drug Administration in 1994 for use in alcoholism treatment. The newer nalmefene is a "universal" opioid antagonist that works on all opioid receptors.

Men and women aged 18-65 years who met Diagnostic and Statistical Manual, Third Edition, Revised criteria for alcohol dependence participated in the study. Dr. Mason and her colleagues randomly assigned 105 of the 162 individuals screened to oral nalmefene at a dose of either 20 mg or 80 mg per day, or to placebo. All patients received professionally delivered, manual-guided, cognitive-behavioral therapy designed to increase their ability to avoid or cope with high-risk situations that can precipitate drinking.

The researchers found no significant differences between the 20 mg and 80 mg nalmefene groups and, therefore, presented their results as nalmefene versus placebo comparisons. Although one-third of the nalmefene patients relapsed to heavy drinking at least once during the 12-week trial, significantly more nalmefene than placebo patients altogether avoided relapse. Of patients who relapsed, those on nalmefene had fewer subsequent heavy-drinking episodes. Patients on nalmefene showed no evidence of medically serious adverse drug experiences and had high rates of medication compliance and treatment completion. The nalmefene and placebo groups did not differ in rates of abstinent days or self-reported craving severity.

"Alcohol consumption is mediated by multiple neurotransmitters and neuromodulators, including nonopioid systems, so that an opioid antagonist alone would not necessarily eliminate alcohol drinking in all alcohol dependent persons," said Dr. Mason. "But any agent that can reduce relapse would be a useful addition in treating alcoholic patients, approximately one-half of whom relapse within the first few months of most behavioral treatments." Several pharmaceutical companies have approached the University of Miami to review the nalmefene data in support of a new drug application to the FDA, Dr. Mason said.

"As neuroscience research advances knowledge of how alcohol acts on the brain, that knowledge will continue to be applied to develop new medications," said Richard Fuller, M.D., Director, Division of Clinical and Prevention Research, NIAAA. "Medications development is a top NIAAA priority."

"A Double-Blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence" was conducted at the University of Miami School of Medicine Alcohol Disorders Research Clinic, Jackson Memorial Medical Center, Miami, Florida, with support from NIAAA. Through grants to researchers in medical and academic institutions, NIAAA supports an estimated 90 percent of alcohol research conducted in the United States.


Story Source:

The above story is based on materials provided by NIH-National Institute On Alcohol Abuse And Alcoholism. Note: Materials may be edited for content and length.


Cite This Page:

NIH-National Institute On Alcohol Abuse And Alcoholism. "Alcohol Researchers Identify New Medication That Lessens Relapse Risk." ScienceDaily. ScienceDaily, 1 September 1999. <www.sciencedaily.com/releases/1999/09/990901075829.htm>.
NIH-National Institute On Alcohol Abuse And Alcoholism. (1999, September 1). Alcohol Researchers Identify New Medication That Lessens Relapse Risk. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/1999/09/990901075829.htm
NIH-National Institute On Alcohol Abuse And Alcoholism. "Alcohol Researchers Identify New Medication That Lessens Relapse Risk." ScienceDaily. www.sciencedaily.com/releases/1999/09/990901075829.htm (accessed September 2, 2014).

Share This




More Mind & Brain News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
Coffee Then Napping: The (New) Key To Alertness

Coffee Then Napping: The (New) Key To Alertness

Newsy (Aug. 30, 2014) Researchers say having a cup of coffee then taking a nap is more effective than a nap or coffee alone. Video provided by Newsy
Powered by NewsLook.com
Young Entrepreneurs Get $100,000, If They Quit School

Young Entrepreneurs Get $100,000, If They Quit School

AFP (Aug. 29, 2014) Twenty college-age students are getting 100,000 dollars from a Silicon Valley leader and a chance to live in San Francisco in order to work on the start-up project of their dreams, but they have to quit school first. Duration: 02:20 Video provided by AFP
Powered by NewsLook.com
Baby Babbling Might Lead To Faster Language Development

Baby Babbling Might Lead To Faster Language Development

Newsy (Aug. 29, 2014) A new study suggests babies develop language skills more quickly if their parents imitate the babies' sounds and expressions and talk to them often. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins